Intraperitoneal Paclitaxel With NALIRIFOX for Pancreatic Ductal Adenocarcinoma With Peritoneal Carcinomatosis
Phase 1
10
about 4.6 years
18+
1 site in CO
What this study is about
This trial is testing whether a treatment of intraperitoneal paclitaxel and intravenous NALIRIFOX is safe and effective in adults with pancreatic cancer that has spread to the peritoneum. Participants will receive these treatments through an abdominal port, along with checkups, lab tests, and imaging scans to monitor their response.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take NALIRIFOX
- 2.Take Paclitaxel
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
paclitaxel (Taxane chemotherapy; stabilizes microtubules)
injection, intravenous
Primary: Adverse event rate
Secondary: Objective response rate, Overall survival, Progression-free survival